Abstract
Introduction Several epidemiologic studies have provided suggestive evidence of a link between coetaneous malignant melanoma (CMM) and breast cancer. The Breast Cancer Linkage Consortium (BCLC) reported approximately 2.6-fold increase in the risk for CMM among BRCA2 carrier families. Methods To evaluate the role of BRCA1/2 mutations in CMM, we screened 92 Jewish patients of Ashkenazi origin diagnosed with CMM for the three Ashkenazi founder mutations: 185delAG and 5382insC in the BRCA1 and 6174delT in the BRCA2 gene. Information about personal demography, family history of cancer, and occupational and lifestyle history was collected. Results Thirty-seven of 92 (40.2%) CMM patients reported a family history of cancer in a first-degree relative. In 14 patients, history of breast cancer (BC) was recorded; however, no family had features associated with BRCA carrier status (i.e., young age at BC onset, history of several BC cases or ovarian cancer in the family). None of the patients were found to carry any of these three mutations. Conclusion Our results suggest a limited role for the three Ashkenazi BRCA founder mutations in CMM risk among the Ashkenazi Jewish population. Therefore, screening patients with CMM for these BRCA1/2 mutations is not warranted.
Similar content being viewed by others
References
Stahl S, Bar-Meir E, Friedman E et al (2004) Genetics of melanoma. Isr Med Assoc J 6:774–777
The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310–1316. doi:10.1093/jnci/91.15.1310
Easton DF, Steele L, Fields P et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12–13. Am J Hum Genet 61:120–128. doi:10.1086/513891
Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365–1372
Thompson D, Easton DF (2002) The Breast Cancer Linkage Consortium cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365
Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408. doi:10.1056/NEJM199705153362001
Begg CB (2002) On the use of familial aggregation in population based case probands for calculating penetrance. J Natl Cancer Inst 94:1221–1226
Gruber SB, Petersen GM (2002) Cancer risks in BRCA1 carriers: time for the next generation of studies. J Natl Cancer Inst 94:1344–1345
Niell BL, Rennert G, Bonner JD et al (2004) BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 96:15–21
Yossepowitch O, Olvera N, Satagopan JM et al (2003) BRCA1 and BRCA2 germline mutations in lymphoma patients. Leuk Lymphoma 44:127–131. doi:10.1080/1042819021000040332
Hubert A, Peretz T, Manor O et al (1999) The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 65:921–924. doi:10.1086/302525
Phelan CM, Kwan E, Jack E et al (2002) A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Hum Mutat 20:352–357. doi:10.1002/humu.10123
Iscovich J, Abdulrazik M, Cour C et al (2002) Prevalence of BRCA2 6174delT mutation in Israeli uveal melanoma patients. Int J Cancer 98:42–44. doi:10.1002/ijc.10155
Hearle N, Damato BE, Humphreys J et al (2003) Contribution of germline mutations in BRCA2, P16 (INK4A), P14 (ARF) and P15 to uveal melanoma. Invest Ophthalmol Vis Sci 44:458–462. doi:10.1167/iovs.02-0026
Landi MT, Goldstein AM, Tsang S et al (2004) Genetic susceptibility in familial melanoma from northeastern Italy. J Med Genet 41:557–566. doi:10.1136/jmg.2003.016907
Goggins W, Gao W, Tsao H (2004) Association between female breast cancer and cutaneous melanoma. Int J Cancer 111:792–794. doi:10.1002/ijc.20322
Hemminki K, Vaittinen P, Easton D (2000) Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes. Int J Cancer 88:87–91. doi:10.1002/1097-0215(20001001)88:1 ≤ 87::AID-IJC14 ≥ 3.0.CO;2-F
Evans HS, Lewis CM, Robinson D et al (2001) Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility. Int J Cancer 94:758–759. doi:10.1002/ijc.1534
van Asperen CJ, Brohet RM, Meijers-Heijboer EJ et al, Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON) (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42:711–719 doi: 10.1136/jmg.2004.028829
Lubinski J, Phelan CM, Ghadirian P et al (2004) Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer 3:1–10. doi:10.1023/B:FAME.0000026816.32400.45
Kadouri L, Easton DF, Edwards S et al (2001) CAG and GGC repeat polymorphism in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer 85:36–40. doi:10.1054/bjoc.2001.1777
Kadouri L, Kote-Jarai Z, Hubert A et al (2004) A single nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 but not in BRCA1 carriers or non-carriers. Br J Cancer 90:2002–2005. doi:10.1038/sj.bjc.6601837
Kadouri L, Kote-Jarai Z, Easton EF et al (2004) Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. Int J Cancer 108:399–403. doi:10.1002/ijc.11531
Wang SC, Makino K, Su LK, Pao AY, Kim JS, Hung MC (2001) Ultraviolet irradiation induces BRCA2 protein depletion through a p53-independent and protein synthesis-dependent pathway. Cancer Res 61:2838–2842
Galper S, Gelman R, Recht A, Silver B, Kohli A, Wong JS et al (2002) Second non-breast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 52:406–414. doi:10.1016/S0360-3016(01)02661-X
Author information
Authors and Affiliations
Corresponding author
Additional information
Dr. Mark Temper is an equal contributor to the manuscript.
Rights and permissions
About this article
Cite this article
Kadouri, L., Temper, M., Grenader, T. et al. Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin. Familial Cancer 8, 29–32 (2009). https://doi.org/10.1007/s10689-008-9206-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-008-9206-8